Thomas Barwick/DigitalVision via Getty Images Topline Summary and Update Cellectar Biosciences, Inc. (NASDAQ:CLRB) is a radiopharmaceutical-focused developmental biotech training their sites on a first approval in Waldenstrom's macroglobulinemia, a type of slow-growing non-Hodgkin lymphoma that does not have many options for patients who progress in their disease. When I first covered them back in February, I warned readers that this company had the air of something big brewing while the market appears  ...